(Press-News.org) EBMT partners in a new consortium to decentralise CAR-T cell therapy and improve hospital workflow
Barcelona, Spain - 26th August 2025 - The newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will develop a fully automated, hospital-based platform capable of manufacturing personalised cell therapies within a few days. Fresenius SE & Co. KGaA is leading this €8 million EU-backed effort to make CAR-T cell therapy faster, more affordable, and more accessible to patients across Europe.
EASYGEN has been selected under the Innovative Health Initiative’s (IHI) call that targets user-centred technologies to relieve hospital staff and broaden access to advanced treatments. EASYGEN meets this goal by enabling rapid, in-hospital CAR-T cell production in days rather than weeks, accelerating patient access, reducing workloads, and lowering costs. EASYGEN leverages technology originally developed by Fresenius Kabi’s Cell and Gene Therapy team.
CAR-T therapy is a breakthrough cancer treatment, yet fewer than 20% of eligible patients currently receive it. It involves genetically modifying a patient’s T cells to target cancer, requiring complex, time-intensive production in specialised facilities often far from patients. Limited manufacturing capacity and supply chain delays prevent timely patient access.
As one of the eighteen consortium partners, EBMT will participate in a study examining current CAR-T treatment processes. EBMT will conduct a literature review on the quality of life of patients treated under existing CAR-T delivery models and will also contribute to patient education and advocacy efforts.
The scientific strategy is academically co-led by Fraunhofer Institute IZI, Leipzig - Europe’s foremost immunotherapy research centre under the leadership of Prof. Dr Michael Hudecek a leader in CAR-T cell engineering and Prof. Dr. Ulrike Köhl, a pioneer in translational cellular immunotherapies.
EBMT's contribution will draw on the experience from the Transplant Complications and Cellular Therapy and Immunobiology Working Parties as well as the Patient Advocacy Committee.
Consortium partners – 18 organizations across 8 countries
Industry & clinical leaders: Fresenius SE & Co. KGaA (Coordinator) (DE), Helios Hospital Berlin-Buch (DE), QS Instituto (ES), Fenwal Inc. (US), Cellix Ltd. (IE), Charles River (DE), Pro-Liance Global Solutions (DE), TQ Therapeutics (DE), Philips Electronics Nederland B.V. (NL).
Academic & research institutions: Fraunhofer IESE (DE), Fraunhofer IZI (DE), Helmholtz-Zentrum Dresden-Rossendorf (DE)Technical University of Denmark (DK), Frankfurt School of Finance & Management (DE), European Society for Blood & Marrow Transplantation (SP), Bar-Ilan University (IL), University of Glasgow (UK), University of Navarra (ES).
About EASYGEN
EASYGEN is a five-year research project supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194710. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and industry partners. Selected under the IHI call “User-centric technologies and optimized hospital workflows for a sustainable healthcare workforce”, the project aims to develop an integrated, automated platform that enables point-of-care CAR-T cell manufacturing—cutting production time, reducing costs, and expanding access to next-generation immunotherapies.
About EBMT:
The EBMT is a non-profit medical and scientific organisation established in 1974 which hosts a unique patient registry providing a pool of data to perform studies and assess new trends. We aim to be the connection between patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies. Our community of healthcare professionals is focused on innovation, research and the advancement of these fields to save and improve the lives of patients with blood-related disorders.
For more information, please visit www.ebmt.org.
Follow @TheEBMT on X, LinkedIn, Facebook and YouTube
Press Contact :
Mélanie Chaboissier
Communication Coordinator, EBMT
Email: melanie.chaboissier@ebmt.org
END
Longer thumbs mean bigger brains, scientists have found - revealing how human hands and minds evolved together.
Researchers studied 94 different primate species, including fossils and living animals, to understand how our ancestors developed their abilities. They found that species with relatively longer thumbs, which help with gripping small objects precisely, consistently had larger brains.
The research, published today (Tuesday, 26 August) in Communications Biology, provides the first direct evidence that manual dexterity and brain evolution are connected across the entire primate lineage, from lemurs to humans.
Humans and our extinct ...
Researchers have shown for the first time how hidden motions could control how granular materials such as soil and snow slip and slide, confirming a long-suspected hypothesis. The knowledge could help in understanding how landslides and avalanches work and even help the construction industry in the future.
Scientists have found sneaky swirls and loops of movement in materials such as soil and snow could influence how materials move. The knowledge could be invaluable in understanding how avalanches and landslides on Earth and Mars speed up or slow ...
Volcanoes that blast gases high into the atmosphere not only change global temperatures but also influence flooding in unusual ways, Princeton researchers have found.
In an August 26 article in the journal Nature Geoscience, the researchers reported that major eruptions create distinct patterns of flooding depending on the location of the volcano and the dispersal of its plume. The patterns mostly divide along the line of the equator. When a volcano’s plume is generally contained in one hemisphere, flooding decreases in that hemisphere and ...
UCLA scientists have developed the first comprehensive road map showing how the ovarian reserve forms in primates, providing crucial insights into women’s health that could revolutionize treatments for infertility and hormonal disorders such as polycystic ovary syndrome, or PCOS.
The research, detailed in Nature Communications, represents a six-year collaboration among scientists from UCLA, Harvard, UC San Francisco and the National Institutes of Health-funded Oregon National Primate Research Center.
The ovarian reserve — the lifetime supply of eggs that a woman ...
EMBARGOED by Springer Nature until 10 a.m. GMT, Aug. 26, 2025
Contact: Maria Ober, mpober@bu.edu, 617-224-8963
(BOSTON) – People with type 2 obesity-driven diabetes tend to have more aggressive breast cancers, but no one knows exactly why. A new study by researchers at Boston University Chobanian & Avedisian School of Medicine and published in Springer Nature found that tiny particles in the blood, known as exosomes, which are altered by diabetes, can reprogram immune cells inside tumors making them weaker and allowing ...
Three widely used artificial intelligence chatbots generally do a good job responding to very-high-risk and very-low-risk questions about suicide, but they are inconsistent in answering questions about suicide that may pose intermediate risks, according to a new RAND study.
Examining ChatGPT by OpenAI, Claude by Anthropic, and Gemini by Google, researchers found that ChatGPT and Claude generated appropriate responses to very-low-risk suicide-related questions and avoided direct responses to very-high-risk suicide-related questions that might encourage self-harm. Responses from Gemini were more variable.
Very-high-risk ...
Osaka, Japan - Researchers at The University of Osaka have developed a novel technique to enhance the performance and reliability of silicon carbide (SiC) metal-oxide-semiconductor (MOS) devices, a key component in power electronics. This breakthrough utilizes a unique two-step annealing process involving diluted hydrogen, to eliminate unnecessary impurities and significantly improve device reliability.
SiC power devices offer superior energy efficiency compared to traditional silicon-based devices, making them ideal for applications like electric vehicles and renewable energy systems. However, previous attempts to improve ...
Ann Arbor, August 26, 2025 - An analysis using data from the National Health and Nutrition Examination Survey (NHANES) among 5,374 women of reproductive age indicates that two thirds of women within this demographic have at least one modifiable risk factor, such as low folate status or unmanaged diabetes, that can increase the chance of serious birth defects. The new study appearing in the American Journal of Preventive Medicine, published by Elsevier, highlights that identifying and addressing these changeable risk factors, especially before pregnancy, are important for public health programs and healthcare providers ...
MANCHESTER, UK, 26 August 2025 -- In a revealing Genomic Press Interview published today in Brain Medicine, Professor Alexei Verkhratsky dismantles decades of neuroscience orthodoxy with discoveries that position neuroglia as active architects of brain function rather than passive cellular bystanders. The Ukrainian-born scientist, whose journey from Soviet-era Kiev to Manchester spans four decades of transformative research, presents compelling evidence that treating brain disorders requires fundamentally rethinking how we approach neurological therapeutics by targeting neuroglia.
The interview unveils a remarkable scientific odyssey. Starting with patch-clamp precursor techniques ...
BRISBANE, Queensland, AUSTRALIA, 26 August 2025 — In a compelling interview with Genomic Press, published today in Genomic Psychiatry, Dr. Miguel E. Rentería reveals how his journey from Mexico to becoming one of Australia's most influential neuroscientists exemplifies the transformative power of curiosity, determination, and global scientific collaboration. The piece showcases a researcher whose innovative combination of genomics, neuroscience, and cutting-edge data science is poised to revolutionize how we understand and treat Parkinson's disease and psychiatric conditions ...
